NCT02025985 - Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | Biotech Hunter

Enrollment

116

Participants

Timeline

Start Date

April 9, 2014

Primary Completion Date

January 24, 2017

Study Completion Date

March 29, 2017

Conditions

Ovarian CarcinomaEndometrial CarcinomaCervical Carcinoma

Interventions

DRUG

Selinexor

"Route of administration and dosage form: Oral tablet; Doses: 35 mg/m\^2 BIW, 35 mg/m\^2 QW, 50 mg/m\^2 BIW, 50 mg/m\^2 QW, 60 mg/m\^2 BIW, 60 mg/m\^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles."

Trial Locations (4)

B-3000

UZ Leuven - Universitair Ziekenhuis Leuven, Leuven

DK-9100

Aalborg University Hospital, Aalborg

DK-2100

Rigshospitalet, Copenhagen

DK-2730

Herlev Hospital, Herlev